RAC - Charts & Price Action, page-21184

RC220 has been designed so it is identical in patients as the original formulation (RC110). Achieving this was the hardest thing about the RC220 reformulation effort. In most reformulation programs you want to change the in-patient properties of your drug (PK/PD), for example, you want to slow the metabolism of the drug, better target to the tissue of interest, or create a slow release version. In our case we want to keep the PK/PD identical to the old formulation so we could continue to rely on all the historical data, but just overcome the crystallisation in the blood problem that caused bisantrene to be commercially dropped by Lederle back in the 1980s. They tried very hard to do what we have accomplished, but the tools they had at their disposal were just too primitive.

Achieving this outcome really was not easy and it took some real lateral thinking from all of us at RAC to solve.

Edit. This was a reply to @flotsam222